Stentys SA (EPA:STNT) hopes to widen its footprint in Asia with the help of a few new distribution deals in the region.
Stentys
Earnings boost, Wall Street dip for Stentys
Medical device maker Stentys SA (EPA:STNT) reported a big boost to its top line, but that didn’t win the company much love from Wall Street last week.
Stentys’ new CE Mark indications expand its potential PCI footprint
Regulators in Europe handed Stentys SA (EPA:STNT) expanded indications for its self-apposing stent, opening up new potential patient populations.
Stentys enrolls 1st patient in U.S. stent trial
Stentys SA (EPA:STNT) hoping a new U.S. clinical trial will help it win pre-market approval for a self-apposing coronary stent.
The Princeton, N.J.- and Paris-based medical device company said it enrolled the 1st patient in its Apposition V trial, under an investigational device exemption from the U.S. watchdog agency.
ACC.13 Roundup: A big week for Medtronic’s Symplicity high blood pressure device
Stentys lands FDA nod to launch 1st U.S. trial with novel Self-Apposing stent
Stent maker Stentys SA (EPA:STNT) won FDA investigational device exemption to launch its 1st U.S. clinical trial of its Self-Apposing stent that it hopes to use in support of a premarketing approval bid.
The announcement was made as the company, in a separate release, unveiled interim results of its Apposition III trial during the Transcatheter Cardiovascular Therapeutics conference in Miami this week.
MassDevice.com +7 | The top 7 med-tech stories for the week of June 22, 2012
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
MassDevice.com +3 | The top 3 med-tech stories for June 19, 2012
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Stentys’ Apposition stent goes head-to-head against Medtronic’s Resolute | Studies Roundup
Stentys SA (EPA:STNT) is looking to prove its next-generation Apposition IV stent in a head-to-head study against Medtronic’s (NYSE:MDT) Resolute.
EuroPCR: Sapien win, promising post-approval results weigh in Edwards’ favor
Leerink Swann analysts saw promise in a pair of "tidbits" about Edwards Lifesciences’ (NYSE:EW) Sapien XT transcatheter aortic valve implantation system presented at the EuroPCR conference in Paris this week.
St. Jude Medical wins CE Mark, launches Enlightn renal denervation system | MassDevice.com On Call
MASSDEVICE ON CALL —St. Jude Medical (NYSE:STJ) landed CE Mark approval and announced commercial launch for its Enlightn renal denervation system as a treatment for hypertension.